CA1277235C - Sustained-release formulation containing an amino acid polymer with alower alkyl (c -c ), polar solvent - Google Patents
Sustained-release formulation containing an amino acid polymer with alower alkyl (c -c ), polar solventInfo
- Publication number
- CA1277235C CA1277235C CA000515031A CA515031A CA1277235C CA 1277235 C CA1277235 C CA 1277235C CA 000515031 A CA000515031 A CA 000515031A CA 515031 A CA515031 A CA 515031A CA 1277235 C CA1277235 C CA 1277235C
- Authority
- CA
- Canada
- Prior art keywords
- sustained
- dosage form
- agent
- ophthalmic
- release dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Abstract
SUSTAINED-RELEASE FORMULATION CONTAINING AN
AMINO ACID POLYMER WITH A LOWER ALKYL (C1-C4), POLAR SOLVENT
ABSTRACT OF THE DISCLOSURE
A sustained-release polymeric hydrogel dosage form useful for topical, systemic or transdermal administration of a medicinal agent comprising a cross-linked, polymerized hydrophobic polymer, an amino acid polymer, a cross-linking agent, and an optional hydrophobic monomer and/or a chain regulator in conjunction with a lower alkyl (C1-C4), polar solvent and said medicinal agent in a therapeutically effective amount.
AMINO ACID POLYMER WITH A LOWER ALKYL (C1-C4), POLAR SOLVENT
ABSTRACT OF THE DISCLOSURE
A sustained-release polymeric hydrogel dosage form useful for topical, systemic or transdermal administration of a medicinal agent comprising a cross-linked, polymerized hydrophobic polymer, an amino acid polymer, a cross-linking agent, and an optional hydrophobic monomer and/or a chain regulator in conjunction with a lower alkyl (C1-C4), polar solvent and said medicinal agent in a therapeutically effective amount.
Description
~277;~3S
BACKGROUND OP THE INVENTION
.
Field of the In~lention This invention relates generally to a novel sustained-release formula-tion which gradually releases a medicinal agent therefrom. More specifically, 5 the invention pertains to the use of the formulation for slowly dispenslng a drug in the eye.
Description of Related Art It is basicaUy known in the art that medicinal1y active substances may t be dissolved in the aqueous constituent of hydrogels to gradually release such substances over an extended period. For example, U.S. Patent No. 3,220,960 describes utilizing a hydrogel in the eye as a carrier for ti~ne release medicaments such as boric acid or penicillin. Similarly, U.S. Patent Nos.
3,551,556; 3,641,23q; ~,003,991; and 4,271,143 disclose slowly releasing an 15 active ingredient from an insoluble, cross-linhed hydrogel in one form or another. Several compositions illustrated in the latter two patents are comprised of viscous, long-acting gel preparations where the prolongation of biological activity of the ophthalmic drug results from a slow erosion of the gel surface. The formulation in U.S. Patent No. 3,551,556 shows granular 20 non-ionogenic, neutral, insoluble hydrogels which are useful for oral or intramuæular application. Further, many patents are directed to ocular insert devices which prolong the effect of a drug incorporated within the device.
Such patents include U5 Patent Nos. 3,811,4~4; 3,826,258; and 3,786,812~
These prior carriers of medicaments present certain difficulties during 25 their use, particularly with ophthalmic drugs. The predominant complaint withlong-acting gel Iormulations is blurred vision. Another difficulty is the inability to wear corrective contact lenses when a viscous material will be instilled and remain in the e~e over an ehtended period of time. The ocular insert devices also present certain disadvantages with their use. When 30 inserted into the conjunctival sac, such devices create a strong foreign bodysensation and discomfort for the patient. The insert devices must be changed ~ J ~ ~
.
~ ' ' ' ' ' ~ :' ' .', .
, ' :
: . ' , ~2~7~:3S
weehl~. Additionall~, the devices tend to fall out of the e~e easil~ and cannot be used further b~ the patient since the~ are not capable of being sterili~ed.
Similarl~, conventional contact lenses containing a sustained-release medicine carrier have drawbachs in practice. They have been found to obtain S inadeguately controlled or prolonged release characteristics mahing the con-ventional lenses unsuitable and impractical as sustained-release devices. The concept of soaking a high water content material in a drug solution has been used with conventional h~drox~ethyl methacr~late based contact lenses, for exampl~ a poly meri2ed hydrophilic monomer or soft contact lens such as 10 So~ens(~) manufactured b~ Bausch ~ Lomb. See Ruben et al., British J.
Ophthal., 59:g55 ~1975). In practice, Soflens~) however, provides an inefficient s~stem and is an unsuitable devic~e for prolonged release.
E2~perimental studies have shown that Soflens~)will release 1009t of pilocar-pine h~drochloride in buffered saline and distilled water in merely 1 1/2 and 15 21/2 hours, respectively. '~
:
' .
:
-~ :
. ~
~277~35 SUMMARY OF THE INVENTION
According to an aspect of the invention, a sustained-release polymeric hydrogel dosage form useful for topical, systemic or transdermal administration of a meidicnal agent comprises cross-linked, polymerized hydrophilic polymer, including an amino acid moiety in the polymer in conjunction with a lower alkyl (C1-C4) polar solent and the medicinal agent in a therapeutically effective amount. Optionally, one of more hydrophobic polymers may be included.
According to another aspect of the invention, a process for preparating the sustained-release dosage form comprises mixing a hydrophilic monomer, an amino `
acid monomer, a cross-linking agent and a lower alXyl (Cl-C4), and a polar solvent. The mixture is polymerized at room temperature. A medicinal agent is added and the mixture cross-linked. Optionally a hydrophobic polymer may be included in the mixture.
Advantages realized by the invention include providing a sustained-release polymeric hydrogel dosage form which does not undergo decomposition or deterioration in body fluids and is non-toxic therein.
The hydrogel dosage form is useful for topical, systemic - or transdermal administration of medicinal agents, such as ophthalmic drugs. The hydrogel dosage form may b~ in the form of a polymeric mix which is moldable to any desired shape, with moldability to the shape of the cornea of the eye being possible. Use of the sustained-release dosage form for ophthalmic administration does not affect eyesight and is well tolerated and pleasing to the user. When used as a contact lens, the ophthalmic dosage formed can concurrently correct vision and release medication to the eye. Hence such contact lens has both cosmetic and therapeutic value.
.~
-, - .
~7723~;
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, the formulation employed as a sustained-release dosage form includes one or more hydrophilic polymers having an olefinic bond, an alpha-, beta-unsaturated carbonyl modified or S unmodified amino acid polymer, a cross-linking agent, a lower alkyl ICl-C4) alcohol and optionally one or more h~drophobic poly mers and/or a chain regulator. The formulation contains a medicinal agent for the controlled-release administration to mammals of the desired active ingredient from the polymeric matrices.
The h~drophilic monomer used in the polymer of this invention can be present in varying amounts, desirably about 50 ~ t~ about 90 9t w/w and, more preferably, about 74 ~c to about 84 4c w/w of the total monomers present in the polymeri2ation mihture. These monomers have an olefinic bond. They include, for e~-ample, the hydroxyalhyl esters and amides, both N-substituted 15 and unsubstituted, of alpha-, beta-unsaturated carboh~lic acids, N-vinyl lactams and 2-acrylamido-2-methylpropane sulfonic acid. The alpha-, beta-unsaturated acids useful in this invention are acrylic acid, crotonic acid, methacr~lic acid, itaconic acid, maleic acid, maleic anhydride, fumaric acid ~nd the lihe. The poly-functional alcohols which form the hydroxyalhyl esters 20 iwlude glycol, gl~cerol, propylene gl~col, trimethylene glycol and other polyhydric alhanols, dialkylene glycols of 2 to 12 carbon atoms, pol~alkylene glycols, etc. Pol~alhylene gl~cols are e~ernplified by triPth~lene glycol, tetraethylene glycol, pentaethylene gl~col, he~aeth~lene gl~col and the lihe.
The preferred h~drophilic monomers are the h~dro~yalh~/l esters, specificall~
2S hydroxyeth~l methacrylate (HEMA).
Useful amides of the foregoing acids include diacetone acrylamide and N-mono-substituted diacetone acrylamide. Also useful are the amines of the foregoing acids such as mono- or di-alhylRmino substituents.
A nitrogen containing monomer which may be used in the preparation of 30 the polymers and copolymers of this invention is convenientl~ referred to as N-vin~l lactam which includes (a) N-vin~l lactams per se and ~b) other heteroc~clic N-vinyl monomers. Illustrative of the N-vinyl lactams that are employed in this invention are N-vinyl-2-pyrrolidinone, N-~l-methyl vinyl) p~rrolidinone, N-vinyl-2-piperidone, N-vinyl-2-caprolactam and the like which ~.~7'723S
may be substituted in the lactam ring by one or more lower ulhyl groups such as methyl, ethyl or propyl, e.g., N-vinyl-5-methyl pyrrolidinone, N-vinyl-3,3-dimethyl pyrrolidinone, N-vinyl-5-ethyl pyrrolidinone, N-vinyl-6-methyl piperidone, etc. Illustrative of the other heterocyclic N-vin~l monomers used 5 in preparing the polymers of this invention are N-vinyl imidazole, N-vinyl succinimide, N-vinyl diglycolylimide, N-vinyl glutarimide, N-vinyl-3-morpholinone, N-vinyl-5-methyl-3-morpholinone, etc. The lactams may be effectively employed alone or in admihture with other lactam monomers to give hydrogels having the foregoing desirable characteristics.
The second monomeric component forming the poly mer of this invention is an alpha-, beta-unsaturated car~onyl modified or unmodified amino acid monomer or monomers. This component can be present in varying amounts, desirabl~ in an amount from about 5 ~ to about 27 ~ w/w and, more preferably, about 6 ~ w/w of the total monomers prese7t in the I5 polymeri2ation mihture. The modified or unmodified amino flcid monomers are hydrophilic compounds which contribute significantly to the swelling of the polymer in water and permit higher oh~gen diffusion.
The alpha-, beta-unsaturated carbonyl modifier for the modified amino acids of this invention may be, for ehample, acrylic acid, crotonic acid, ~0 methacr~lic acid, maleic acid, fumaric acid, itaconic acid and their functional derivatives, i.e~, acid chlorides, anh~drides, amides and esters. The more preferred modifiers are methacrylic acid and methacroyl chloride.
An amino acid is an organic acid ~hose molecule contains both a carbo1~yl group ICOOH) and an amino group (NH2) coupled with an alkyl, 25 c~cloalh~l, aryl or heterocyclic structure, the alkyl, cycloalhyl or heteroeyclic structure being free of olefinic unsaturation. The alpha-, beta-carbonyl substituent can be attached to either the amino group or the hydro~ group of the amino acid, dependi~lg on the structure of the amino acid. Additionally, the carbonyl substituent can attach to other reactive groups, if present, in the30 amino acid, e.g., thiol (SH~ or phenolic hydro~yl.
Amino acids useful in the preparation of the modified acids of this invention include, but are not limited to, beta-alanine, ~amma-aminobutyric acid, omega-aminocaproic acid, omega-aminododecanoic acid, beta~ycanoala-nine, epsilon-meth~lhistidine, canavanine, djenkolic acid, l-a~aserine, gamma-. ' :
~27723~;
meth~lene glutamic acid, N-meth~ltyrosine, glycine, alanine~ serine, cystine, cysteine, lanthionine, phenylalanine, tyrosine, diiodot~rosine, tryptophan, histidine, aminobutyric acid, methionine, valine, norvaline, leucine, isoleucine, norleucine, arginine, ornithine, lysine, aspartic acid, glutamic acid, threonine, S hydrohyglutamic acid, proline, hydro~yproline, asparagine, glutamine, desmosine, isodesmosine, 5-h~drosylysine and the lihe. Preferred AminO acids are glycine, glutamic acid, desmosine and isodesmosine.
It should be understood that other, though perhaps less common, amino acids occurring in nature or prepared synthetica]lly, including those shown in lO the ehamples which follow, are within the scope of this invention. Reactive sites on the amino acids can be partially bloched by saturated nonpol~meriz-able subs~ituents provided that one reactive site is substituted by the alpha-, beta-carbonyl substituent.
The polymers used in this invention are cross-linhed by all types of 15 cross-linking compounds used in the prior art, see for instance, U.S. Patent Nos. 3,822,089; 4,152,508; and 4,4~0,919. The cross-linking agent can be employed in varying amounts and desirably in an amount from about 3 to about 30 parts by weight of the total monomers present. Examples of cross-linking agents include polyfunctional derivatives of the previously enumerated a ha-, 20 beta-unsaturated acids, e.g., acrylic acid, methacrylic acid, crotonic acid, itaconic acid, maleic acid, fumaric acid, acrglamide, methacrylamide, multi-vinyl substituted ben~enes, etc. More particularl~ these cross-linhing agents include, but are not limited to, the following: ethylene glycol diacrylate or dimethacrylate, diethylene glycol diacrylate or dimethacryLqte, triethylene 25 glgcol diacrglate or dimethacrylate, tetraethylene gl~col diacrylate or dimethacrylate, polyethylene glycol diacrylate or dimethacrylate, trimethylol-propane triacrylate or trimethacrylate, bisphenol A diacrylate or dimeth-acrylate, ethoxylated bisphenol A diacrylate or dimethacrylate, pentaery-thritol tri- and tetra-acrylate or methacrylate, tetramethylene diacrylate or 30 dimethacrylate, methylene bisacrylamide or methacrylamide, dimethylene bisacrylamide or methacrylamide, N,N'-dihydroxyethylene bisacrylamide or methacrylamide, heY.amethylene bisacrylamide or methacrylamide, decamethylene bisacrylamide or methacrylamide, divinyl benzene, vinyl ~2~7'~23~
methacrylate, allyl methacrylate, etc. A preferred cross-linking agent is allyl methacrylate.
Still other useful cross-linhing agents include 1,3-bis ~-methacrylo~l o~alhyl) tetra disiloxane and similar poly ~organo-siloxane) monorners set 5 forth in U.S. Patent No. 4,l53,6gl. Another group of useful cross-linhing agents are the resonance free di~alkylene tertiary amine) cyclic compounds, e.g., N,N'~ivinyl ethylene urea, as disclosed in U.~. Patent No. ~,436,887.
Yet another group are di- or polyvinyl ethers of di-- or polyvalent alcohols such as ethylene glycol divinyl ether.
The formulatior~ of the instant invention also contains a lower alhyl (Cl-C~), polar solvent, preferably volatile, demonstrating high water solu~ilityparameters such as a lower alhyl ~CI-Cd,) alcohol, an unmodified or modified hetone and the like for controlling the viscosity of the polymer. Suitable solYents may also include mi~-tures of modified and unmodified hetones in any proportions and mi~tures of a lower alh~l ~CI~Cg) alcohol and water in any proportions. E~amples o~ solvents are methanol, ethanol, propanol, butanol, isopropanol, acetone, methyl eth~l hetone, h~dro~yacetone, etc. Typically, equal parts of solvent and linear, poly meri~ed poly mer are used in the preparation of the formulation. However, different amounts of the solvent 20 may be used with the polymer though generally less conveniently. When the process of this invention is followed, the residue of the solvent remains in theformvlation in varying amounts depending upon reaction conditions such as time and temperature. Preferabl~ trace amounts of the residue are present for ophthalmic use and higher amounts are present for transdermal use.
Optionall~, a chain regulator or chain transfer a~ent may be added if a particular monomerffolvent combination requires ;t. ~or e~ample, certain combinations containing solvents such as butanol may require large quantities of butanol which may not be desirable in the product. If a chain regulator is added, a smaller amount of butanol may be used.
3~ The term "chain regulator" refers to any chemical that controls the molecular weight of the pol~mer during polymerization. A chain regulator may be optionally emploS~ed in var~ing amounts and desirably in an amount from about 0.01 4t w/w to about 0.5 ~ w/w. Ehamples of chain regulators include, but are not limited to, dodecanethiol, isopropyl mercaptan, 7~3S
decanethiol and the lihe. A particularly preferred chain regulator is dodecanethiol.
Por some applications the polymeri~ates formed from the above hydro-philic monomer(s), modified or unmodified amino acid monomer~s), cross-5 linking agent(s), a lower alhyl (Cl~Cg) alcohol snd an optional chain regulatormay lack the desired physical handling properties. It is another aspect of this invention in such circumstances to incorporate one or more hydrophobic monomers in the above polymers in varging amounts, desirably from about 8 t to about 20~ w/w of the total monomers present. nqore preferably the 10 hydrophobic monomer would be present in an amount of about lO ~c w/w of the total monomers present. Among other things, the hydrophobic monomers are useful as modulus modifiers.
The modulus modifier may be, Ior eY.ample, cycloalhyl ester, tertiary-but~l styrene, polycyclic acrylate or rnethacrylate, and the lihe as well as 15 mi~tures thereof. More particularly the polycyclic modifiers mag be isobornylacr~late, isobornyl methacrylate, dic~clopentanedienyl acrylate, dic~clopen-tanedien~l methacrylate, adamantyl acrylate, adamantyl methacryl~te, isopinocamphyl acr~late, isopinocamph~l methacrylate, etc. and mixtures thereof. The cycloalhyl ester modifier is of formula I below. Illl~strative of 20 these cycloalhyl modifiers are menthyl methacrylate, menthyl acrylate, tertiarybut~l cyclohe~yl methacr~late, isohe~l cyclopentyl acr~late, meth~lisopentyl cyclooctgl acrylate snd the like.
- ~ O -- C ~ ~ Y ~2 ~ ~ ~
S I ) J ~ E
Z~ D
~(C~2) n~
wherein: ~
30 D is branched or normal alh~l of 3 to 6 carbon atoms E is H or CH3 Z is H or CH3 - l u -~2'7~Z3~
n is an integer from 3 to 8.
In addition to the modulus modifiers other well hnown hydrophobic monomers ma~ be used in the formulation of the pol~rners and copolymers of this invention to further tailor the properties to the particular application.
5 The h~drophobic monomers of this invention include monomers which contain at least one silicon or fluorine atom as a part of its composition. Hydrophobic monomers include alhyl, c~clo-alhyl and aryl acrylates and methacr~lates as well as mono- or disubstituted itaconates, styrene and its derivatives, acr~lonitrile, vin~l esters such as vinyl acetate or vin~l pentacet~l gluconate,10 vin~l ethers such as vinyl butyl ether, allyl esters such as all~l acetate, propionate or butyrate, fluorine containing monomers such as octafluoropenty1 methacrylate and silicon containing monomers, e.g., 1,1,1-tris ;trimethoky-silox~) -3-methacrylox~-prop~lsilane or heptameth~ltrisilo~-anyl ethyl acrylate The monomeric mixtures, comprising the hydrophilic mondmer(s), the 15 modified or unmodified amino acid monomer(s), the optional hydrophobic monomer(s), the cross-linhing agent, the lower alhyl (Cl-C4) alcohol and ~he optional chain regulator are generally clear, colorless liguids of vary ing viscosity. These monomer mixtures are polymeri~ed but not cross-linhed using ultraviolet light at room temperature. According to the process of this 20 invention, the medicinal agent dissolves in this linear, pol~meri2ed pol~mer that can then be cross-linhed b~ ultraviolet light and/or heat. Before cross-linhing takes place, the linear polymer is characteri~ed by being soluble in methanol and isopropanol. After cross-linking, an insoluble pol~mer is formed.
As catal~sts for carrying out the pol~meri~ation, there ma~ be 25 employed a free radical catalyst (initiator) in varying amounts and typically in the range of about O.O5t to 3~ w/w of the po1ymeri2able monomer mi~ture.
The preferred amount of catalyst is 0.1~c to ~.5q: w/w OI the total monomers present. Usually, the catalyst is added initially to the monomers and then the pol~meri2ation procedure is completed. The free radical type initiators 30 suitable for this invention include peroxides, a20 compounds, ohidation-reduction systems and similar initiatcrs described in the literature~ Typical catalysts include ben201n methyl ether, tertiary-butyl-peroctoate, benzo~l peroxide, isopropyl percarbonate, meth~l ethyl hetone peroxide, cumene ~;~7723~
hydroperoxide, dicum~l perohide, bis(isopropyl) perohydicarbonate, 2,2'-azobis[isobutyronitrilel, acetyl pero~ide, lauroyl peroxide, decanoyl peroxide, 2t2'-azobis 1 2,4-dimethylvaleronitrile~, phthalic perol-ide, diethok~acetophe-none, tertiary~utyl peroh~pivalate and the lihe. Thermal catalysts, visible 5 light or irradiation, e.g., by ultraviolet light or gamma rays, also can be employed to catal~ze the polymeri2ation. Polymerization can be done at 20 to 150C, usually ~0 to 90C. Prior to adding a mledicament or to cross-linhing the polymer, a prepolymerization of the monomer mi1- may be achieved at room temperature, usuall~ 20 to ~8C, to create a linear, polymeri~ed 10 pol~mer. Cross-linhing ma~ be done using a suitable amount of heat, typically65 to 75C. The choice of cata1~st obviousl~ dlepends upon the temperature desired for the reaction.
Water soluble diluents may be used with the foregoing polymers to modify the physical properties of these pol~ mers. More particularly, the 15 diluents may be advantageous in improving machinability and swell character-istics of the pol~mer. Typically, the amount of diluent will be less than 50 weight percent of the total monomers emplo~ed and preferably not more than 30 weight percent. In a particular polymer system, the limiting amount of diluent is the solubility of the diluent in the monomer system. Thus, there 20 should be no phase separation between diluent and starting monomer mi~ture.
AdditionaUy, el-cessive amounts of diluent will result in collapse of the cell structure of the finished biomedical devices when the device is h~drated, i.e., replacement of diluent by water~ The maximum amount of diluent is readil~
ascertained b~ swelling the diluent free pol~mer in the proposed diluent and 25 measuring the degree of swell. Comparable results are obtained when using solvent soluble diluents wherein the solvent does not affect the lens polymer.
Suitable diluents include ethylene gl~col, gl~cerin, liguid polyethylene glycols, butanol, butanol/water mixtures, ethylene oxide/prowlene o~.ide bloch copolgmers having a molecular weight from 1,000 to 5,ûO0, linear poly(vinyl 30 pyrrolidinone) having a molecular weight from 500 to 10,000, low molecular weight linear poly(hydro~yethyl methacrylate), gl~col esters of lactic acid, formamide, dimethyl formamide, dimeth~l sulfoxide and the lihe. In the finished biomedical device, it will be necessary to replace an~ diluent with an agueous solution. With respect to contact lenses, the final water content of . . .
~ ~r~
the polymeric composition typicall~ ranges from about 25~ to about 70~ w/w.
The contact lens should, of course, contain a physiological saline solution as the aqueous medium.
Using methods well hnown in the art, the sustained-release formulation of this invention can be formed into a variety of shapes depending upon the end use and desired results to be obtained 1therefrom. ~or ophthalmic purposes, the poly meric hydrogel could have an~ form to maintain direct contact with the e~e. It is not necessar~ to cover the entire cornea if the dosage form is merely used to instill a continuous flow of an ophthalmic drug 10 in the eye. If the h~drogel will also be used to corre--t vision, then it m~y be desirable to cast the polymer on an optical mold.
By way of e~ample, the mihture of hydrophilic monomer(s), modified or unmodified amino acid monomerls), cross-linhing agent, free radical initiator and optional hydrophobic monomer(s) described above is prepared. If àesir-15 able, a chain regulator is added to this mi~-ture. Then a lower alhyl (Cl-C4)alcohol is added. A two-stage process is carried out by forming a linear, poly meri2ed poly mer b~ ultraviolet light at room ~emperature and cross-linking the polymer b~ subseguent application of heat together with ultraviolet light if needed.
This invention contemplates a process for preparing the sustained-release poly meric hydrogel dosage form whereby the medicinal agent is retained by the poly meric matri~ and, upon tissue contact, is gradually released into the tissue. The medicinal agent may be dissolved directly into the linear, uncross-linked polymer. The drug becomes intimate1y mil-ed in the 25 polymeric matrix rflther than remaining as particulate matter. Subsequent cross-linhing prevents co~ol~meri2ation of the drug with the pol~mer allowing for greater recovery of the drug upon tissue contact. The drug would release slowly into the tissue for 1OCQ1 or systemic effect over prolonged time intervals at lower concentrations thereb~ eliminating or reducing side effects.
30 The amount of ti~e drug used in the preparation of the dosage forms will varydepending upon the physicochemical properties of the selected drug and the therapeutic effect desired ~o be achieved. l~picall~, the drug is added on a eguivalenc~ basis, that is, an equivalent for eguivalent basis of drug to the .
- ': ~ . ' : ' .
.
~ :, linear, polymeri~ed polymer. Although a stoichiometric number of equivalents of drug and the linear, polymeri2ed polymer is preferred, other amounts can also be used. As an e~.ample of pilocarpine h~drochloride, varying concentrations of the compound may be employed, desirably an amount from 5 about 5~ to about 15~ w/w, of pilocarpine hydrochloride to the weight of ~he linear polymer, and preferably 9.14 w/w, for incorporation in the dosage form.
The polymeric composition of the instant invention provides appreciable time release of the medicament. The release rate of a drug from the polymeric matria varies with cross-linhing density and type of polyrner barrier 10 system. Additionally, the release rate depends upon the viscosity of the linear, uncross-linhed polymer which is controlled by the addition of a polur, volatile solvent such as a lower alhyl (Cl~Cg) alcohol.
To quantify the release rates, lenses with and without drug can be placed in a known guantity of release media ~distilled water or buffered saline)5 and stirred with a magnetic stirrer. At various times the lenses can be transferred to fresh media and the absorbance of the previous media can be determined by ultraviolet spectroscopy. The absorbance of the media containing drugged lenses is reduced by the absorbance of the media contain-ing undrugged lenses. Use of a calibration curve relating absorbance to 20 concentration allows for a determination of the concentration of the drug.
The calibration curve is developed by measuring the absorbance of hnown concentrations of the drug in the release media. As the concentrations !ug/ml) of the drug and the volume ~ml) of release media are hnown, the amount of the released drug can be calcula~ed ~ug). This value divided by the time of 25 e~posure to the media gives the release rate in,llg/hr which is plotted against time.
The contact lenses made from the polymer utili~,ed in the instant invention are ox~gen permeable. A critical ohygen tension and flul. under A
lens should be about 1~ mm Hg and 2,ul/(cmghr.) respectively below which 30 corneal swelling occurs, see Polse and Decker, Investigative_Ophthalmolog~
and Visual Science, 18:t88 11979). In order to meet these requirements, the lens material must have adeguate o~ygen permeability. These more preferred contact lenses have an o~ygen permeability of at least about 241-t0-1 ~
cm3cm/lsec.cm2mmHg), are hydrolytically stable, biologically inert and ~2t~7~3~
transparent. In comparison, the well-hnown COntACt lens polymer polyhydrok~-ethyl methacr~late has an o~-ygen permeability value of about one-third of the polymers of this invention.
Additionally, these lenses are h~drolytically st~ble, meaning that when 5 the cont~ct lenses are placed into an agueous solution (e.g., on the eye) or during the disinfecting step (i.e., water plus heat), the lenses will not change in chemical composition. That is, the~ will not hydroly~e. On heating in boiling water for 120 hours, the typical pol~mer of this invention experiences a water content loss of 3~ or less. The most preferred lenses/polymers useful in this 10 invention have a stable water content that undergoes less than 1~ change.
Thus, the polymers and copol~ ners disclosed herein can be boiled and/or autoclaved in water without being damaged whereby sterilizQtion may be achieved. In addieion, sterilization can be achieved by ~ irradiation, ultraviolet light irradiation and eth~lene oxide e~posure.
The pol~mers and copolymers employed in this invention bei~3g soft yet resilient and hard to tear are well suited for preparing biomedical devices, including contact lenses, which have the ability to release medications from the pol~meric matrih over a prolonged period of time. It is weU hnown that the wearer of soft contact lenses will have an unavoidable amount of handling 20 of the lenses. Part of the cleaning and rinsing procedure is to rub each lens and tearing has been a concern in prior art lenses. The polymers and copol~mers used in the present invention have a tear initiation strength (ASTM
D-1938) of up to 5 g/mm of thichness.
An article formed from the disclosed polymers and copolymers may be 25 used to administer medications to mammals where an article compatible with living tissue or with the mucous membranes is desired. The term "biomedical devices7' means the materials disclosed herein have nonto~ic, nonirritating ph~siochemical properties rendering them suitable for prolon~ed contact with living tissue, blood and the mucous membranes. It is hnown that blood, for 30 e~ample, is rapidl~ damaged in contact with artificial surfaces. The design of a s~nthetic surface which is antithrombogenic and nonhemolytic to blood is necessar~ for drug edministering devices used with blood, especially an implanted or transdermal device. The polymers and copolymers emplo~ed for the purposes of the instant invention are compatible with living tissue.
- ' ' ' The instant invention provides a novel sustained-release poly meric h~drogel dosage form useful for topical, systemic or transdermal administra-tion of a medicinal agent comprising the above-described polymeric matrix in association with a therapeutically effective amount of the medicinal agent.
5 When prepared according to the novel process OI this invention, the polymeric matri1. permits the active ingredient to be subseguently released at a gradual, carefully controlled rate prolonging the time release period. Further, this invention concerns a method of administering a therapeutically effective amount of a medicinal agent over an extended pleriod of time to Q mammal in 10 need of the medicinal agent which comprises contacting a tissue of said mammal with the sustained-release polymeric hydrogel dosage form for a sufficient amount of time to achieve a constant therapeutic effect. In contrast to normal disintegration time, the sustained-release administration of medicaments enhances therapeutic effectiveness and decreases many undesir-15 able side effects by maintaining constant tissue and blood levels.
The po~ meric hydrogel dosage form can be used in preparingbiomedical devices that upon surgical implant will provide sustained-release activity of the active ingredient. Depending on the location of the implant, the therapeutic effect may be local or systemic. The dosage form can also 20 provide for the oral or topical (i.e., locali~ed activity on the shin) controlled-release administration of medicaments. Additionally, the dosage form can be utili~ed for the transdermal controlled-release administration of medicaments, i.e., the device is retained in contact with the skin for transdermal absorptionof the medicament into the blood for systemic effect. Contact with the skin 25 ma~ be achieved by any means we~l-known in the art such as ~ incorporating an adhesive in or on the device, adhering the device within or onto a bandage-type al ticle, etc.
Further, the dosage form c~n be useful for the ophthalmic route of adminis.ering medicinal agents for either local or systemic therapeutic effect.
30 The term "ophthalmic administration of a systemic medicament" defines the administration of a medicinal agent to a mammal ~ the ophthalrnic route whereby the medicinal agent acts therapeutically to create a systemic effect.
For ophthalmic administration of a medicament to produce local or systemic activit~, the polymeric composition can be molded into any convenient shape ' . - ~
. . ~
~277Z3~
for e~e contact. If correcting vision is not necessary, the dosage form does not have to cover the entire cornea. Alternatively, the pol~meric hydrogel can be shaped into contact lenses on optical molds if it is desirable to correctvision in addition to administer ophthalmic medicaments.
The length of time for contac~ing the poly meric h~drogel device containing a medicament with a tissue ~f a mammal depends upon the individual circumstances of each c~se. A sufficient amount of time to achieve a constant therapeutic effect varies in accordance with the optimum thera-peutic effect desired. The duration of therap~ is, of course, contingent upon 10 the disease or medical problem being treated or palliated. Lihewise, the therapeutically ef~ective amount of tl)e specific medicinal agent is determined by therap~ reguirements and the bioph~sical proper~ies of the active compound. For eaample, with respect to contact lenses, the invention contemplates dail~ wear or e~tended wear, typically, up to a month. To traat 15 sn e~e infection, it would be desirable to maintain the contact lens ;containing an antibiotic or an antiviral agent on the eye for one to two weehs. ~n the other hand, to treat glaucoma, it would be desirable to wear the lens containing an agent for reducing intraocular pressure for the ma1-imum time that extended wear eontact lenses can remain in the eS~e.
The term "dosage form" refers to physically discrete un;ts suitable as unitary dosage for mammals, each unit containing a predetermined quantity of ac~ive component calculated to produce the desired therapeutic effect. The novel sustained-release dosage form of this invention is indicated b~ the ph~sical or chemical characteristics of the active component and the 25 particular therapeutic effect to be achieved.
The term "a medicinal agent" means a substance used in treating or ameliorating a disease or medical condition. For purposes OI this invention, "a medicinal agent" refers to drugs which would have the eapacit~ to be bound to the amino acid moiet~ of the polymeric h~drogel. That is, any drug or its salt 3~ with polar characteristics that interacts with amino acids in 8 ~avorable wa~could be used in the present invention. Eaamples of medicinal agents include, but are not limited to, antibiotics, antivirals, anti-inflammatories, steroids, peptides, pol~peptides, cardiotonics, antih~pertensives, antiallergics, alpha-and beta-adrenergic bloching agents, anticataract agents, ophthalmic , ~77~
medicaments, ophthalmic lubricating agents, ophthalmic topical or regional anesthetic agents, etc. The ophthalmic medicaments or other medicinal agents encompass such drugs as pilocarpine, idoxuridine, carbachol, bethanechol, timolol, tetracycline, epinephrine, phenylephrine, eserine, 5 phospholine, demecarium, cyclopentolate, homatropine, scopolamine, nitroglycerin, chlortetracycline, bacitracin, neomycin, polymy~in, gramicidin, oxytetracycline, chloramphenicol, gentamycin, penicillin, erythromycin, sulfacetamide, polymyxin B, tobramycin, isofluorophate, fluoromethalone, de~amethasone, hydrocortisone, fluorocinolone, medrysone, prednisolone, 10 methyl prednisolone, betamethasone, triamcinolone, interferon, cromolyn, all-tr -retinoic acid ~Vitamin A), the nonto~ic, pharmaceutically acceptable salts thereof and the lihe. The category of ophthalmic lubricating agents refers to those agents capable of inducing natural lacrimation or creating artificial lacrimation and includes, for e~ample, polyvin~l alcohol, cellulose 15 polymers such as hydrohypropyl methyl cellulose, a polylactam such as polyvinylpyrrolidinone and other tear inducers or substitutes. The topical or regional anesthetic agents, which may be useful during ophthalmic surgery or other ophthalmic procedures, include lidocaine, cocaine, beno~.inate, dibucaine, proparacaine, tetracaine, etidocaine, procaine, hexylcaine, 20 bupivacaine, mepivacaine, prilocaine, chloroprocaine, etc.
The term "pharmaceutically acceptable salt" refers to those salts of the parent compound which do not significantl~ or adversely affect the pharma-ceutical properties le.~., toxicity, efficacy, etc.) of the parent compound. Thesalts of the present invention which are pharmaceutically acceptable include, ~5 for example, chloride, iodide, bromide, h~drochloride, acetate, nitrate, stearate, phosphate, sulfate, etc. It is desirable to use the appropriate salt form of the active ingredient which would increase the water solubility or polar characteristics of the base compound.
In addition to the medical uses, the above described polymeric hydrogel 30 may be found useful with veterinary products and agricultural chemicals such as pesticides, herbicides and the lihe. For example, a pesticide incorporated into the polymer may be mi~ed with fertili~ers. On spraying, the alcohol evaporates leaving a filn~ which could be made biodegradable.
The following examples demonstrate certain aspects of the present 35 invention. However, it is to be understood that these examples are for ~LZ~7~3~5 illustrative purposes onl~ and do not purport to be wholly definitive as to conditions and scope of this invention. All parts and percents referred to herein are on n weight basis and all temperatures are expressed in degrees Celsius unless otherwise specified. It also should be appreciated that when 5 t~pical reaction conditions ~e.g., temperature, reaction times) have been given, the conditions which are both above and below these specified ranges can also be used, though generall~ less convenientlg.
A further understanding of the invention may be obtainsd from the following nonlimiting examples. These e~amples were conducted at room 10 temperature (about 23C to about 28C) and at atmlospheric pressure.
Esample 1 Preparation of a H~drogel Pol~mer Containing Pilocarpine Hgdrochloride A mihture is prepared b~ combining 7g.5 g of 2-h~dro~yethyl meth-5 acr~late (HEMA) containing 0.12~ of ethylene glycol dimbthacrylatetEGDMA), 1~ g of isoborn~l methacrylate ~IBOMA), 8 g of methacroyl glycine (MG), 2.5 g of ben~oin methyl ether (BME) and 0.1 g of 2, ~'-a~obisl isobu-tyronitrile ~ . To the mihture is added 5 g of allyl methacrylate. To 5 g of themixture is added 5 g of methanol. This mixture is then purged with nitrogen 20 and polymeriæation is performed with stirring under ultra~iolet light (UV) at room temper~ture for 2 hours. When a hone~-lihe consistenc~ develops, 0.205 g of pilocarpine hydrochloride is added to 4 g of the linear polymer forming a clear solution. The solution is cross-linked with a subseguent exposure to UY for 30 minutes at room temperature and then ~o UV for 30 25 minutes at 70C.
E~.ample 2 Preparation of a H~drogel Polymer Containing Pilocar~ne H~drochloride The procedure of Ehample t is repeated to prepare the hydrogel 30 polymer with the additional step of adding 0.01 g of dodecanethiol after the a11yl methacrylate is added to the mikture.
.
, - l9 -E~ample 3 Preparation of a Hydrogel Polymer Containin~ Pilocerpine H~drochloride The procedure of Example t is repeated to prepare the hydrogel polymer with the additional step of adding 0.02 g of dodecanethiol after the Qllyl methacr~late is added to the mixture.
Ehample ~
Preparation of a Hydrogel Polymer Containin~ Pi~chloride The procedure of E~-ample 1 is repeated to prepare the hydrogel polymer with the additional step of adding 0.25 g of dodecanethiol after the allyl methacrylate is added to the mihture.
Example 5 Preparation of a Hydrogel Polymer Containing Pilocarpine H~drochloride The procedure of Eaample I is repeated to prepare the hydrogel polymer with the additional step of adding û.5 g of dodecanethiol after the allyl methacryLqte is added to the mi~ture.
Ehample 6 Preparation of a H~drogel Polymer Containing Nitrogl~cerin The h~drogel polymer of this example is prepared according to the procedure of Ehample I e~cept that 0.025 g of nitroglycerin is substituted for the pilocarpine hydrochloride.
ExamPle 7 Preparation of a H~drogel Polymer Containing Scopolamine The hydrogel polymer of this ex~mple is prepared according to the procedure of E~ample 1 except that 0.2 g of scopolamine is substituted for the 30 pilocarpine hydrochloride.
In the foregoing there has been provided a detailed description of preferred embodiments of the present invention for the purpose of illustration and not limitation. It is to be understood that all other modifications, 35 ramifications and eguivalents obvious to those having skiU in the art based on this disclosure are intended to be within the scope of the invention as claimed.
- . .:
. .~ . . ~
.~' - '- :
. , .';- . ' : , - ' : . . ' '-: " - : .
.
~- - '' ' :
BACKGROUND OP THE INVENTION
.
Field of the In~lention This invention relates generally to a novel sustained-release formula-tion which gradually releases a medicinal agent therefrom. More specifically, 5 the invention pertains to the use of the formulation for slowly dispenslng a drug in the eye.
Description of Related Art It is basicaUy known in the art that medicinal1y active substances may t be dissolved in the aqueous constituent of hydrogels to gradually release such substances over an extended period. For example, U.S. Patent No. 3,220,960 describes utilizing a hydrogel in the eye as a carrier for ti~ne release medicaments such as boric acid or penicillin. Similarly, U.S. Patent Nos.
3,551,556; 3,641,23q; ~,003,991; and 4,271,143 disclose slowly releasing an 15 active ingredient from an insoluble, cross-linhed hydrogel in one form or another. Several compositions illustrated in the latter two patents are comprised of viscous, long-acting gel preparations where the prolongation of biological activity of the ophthalmic drug results from a slow erosion of the gel surface. The formulation in U.S. Patent No. 3,551,556 shows granular 20 non-ionogenic, neutral, insoluble hydrogels which are useful for oral or intramuæular application. Further, many patents are directed to ocular insert devices which prolong the effect of a drug incorporated within the device.
Such patents include U5 Patent Nos. 3,811,4~4; 3,826,258; and 3,786,812~
These prior carriers of medicaments present certain difficulties during 25 their use, particularly with ophthalmic drugs. The predominant complaint withlong-acting gel Iormulations is blurred vision. Another difficulty is the inability to wear corrective contact lenses when a viscous material will be instilled and remain in the e~e over an ehtended period of time. The ocular insert devices also present certain disadvantages with their use. When 30 inserted into the conjunctival sac, such devices create a strong foreign bodysensation and discomfort for the patient. The insert devices must be changed ~ J ~ ~
.
~ ' ' ' ' ' ~ :' ' .', .
, ' :
: . ' , ~2~7~:3S
weehl~. Additionall~, the devices tend to fall out of the e~e easil~ and cannot be used further b~ the patient since the~ are not capable of being sterili~ed.
Similarl~, conventional contact lenses containing a sustained-release medicine carrier have drawbachs in practice. They have been found to obtain S inadeguately controlled or prolonged release characteristics mahing the con-ventional lenses unsuitable and impractical as sustained-release devices. The concept of soaking a high water content material in a drug solution has been used with conventional h~drox~ethyl methacr~late based contact lenses, for exampl~ a poly meri2ed hydrophilic monomer or soft contact lens such as 10 So~ens(~) manufactured b~ Bausch ~ Lomb. See Ruben et al., British J.
Ophthal., 59:g55 ~1975). In practice, Soflens~) however, provides an inefficient s~stem and is an unsuitable devic~e for prolonged release.
E2~perimental studies have shown that Soflens~)will release 1009t of pilocar-pine h~drochloride in buffered saline and distilled water in merely 1 1/2 and 15 21/2 hours, respectively. '~
:
' .
:
-~ :
. ~
~277~35 SUMMARY OF THE INVENTION
According to an aspect of the invention, a sustained-release polymeric hydrogel dosage form useful for topical, systemic or transdermal administration of a meidicnal agent comprises cross-linked, polymerized hydrophilic polymer, including an amino acid moiety in the polymer in conjunction with a lower alkyl (C1-C4) polar solent and the medicinal agent in a therapeutically effective amount. Optionally, one of more hydrophobic polymers may be included.
According to another aspect of the invention, a process for preparating the sustained-release dosage form comprises mixing a hydrophilic monomer, an amino `
acid monomer, a cross-linking agent and a lower alXyl (Cl-C4), and a polar solvent. The mixture is polymerized at room temperature. A medicinal agent is added and the mixture cross-linked. Optionally a hydrophobic polymer may be included in the mixture.
Advantages realized by the invention include providing a sustained-release polymeric hydrogel dosage form which does not undergo decomposition or deterioration in body fluids and is non-toxic therein.
The hydrogel dosage form is useful for topical, systemic - or transdermal administration of medicinal agents, such as ophthalmic drugs. The hydrogel dosage form may b~ in the form of a polymeric mix which is moldable to any desired shape, with moldability to the shape of the cornea of the eye being possible. Use of the sustained-release dosage form for ophthalmic administration does not affect eyesight and is well tolerated and pleasing to the user. When used as a contact lens, the ophthalmic dosage formed can concurrently correct vision and release medication to the eye. Hence such contact lens has both cosmetic and therapeutic value.
.~
-, - .
~7723~;
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, the formulation employed as a sustained-release dosage form includes one or more hydrophilic polymers having an olefinic bond, an alpha-, beta-unsaturated carbonyl modified or S unmodified amino acid polymer, a cross-linking agent, a lower alkyl ICl-C4) alcohol and optionally one or more h~drophobic poly mers and/or a chain regulator. The formulation contains a medicinal agent for the controlled-release administration to mammals of the desired active ingredient from the polymeric matrices.
The h~drophilic monomer used in the polymer of this invention can be present in varying amounts, desirably about 50 ~ t~ about 90 9t w/w and, more preferably, about 74 ~c to about 84 4c w/w of the total monomers present in the polymeri2ation mihture. These monomers have an olefinic bond. They include, for e~-ample, the hydroxyalhyl esters and amides, both N-substituted 15 and unsubstituted, of alpha-, beta-unsaturated carboh~lic acids, N-vinyl lactams and 2-acrylamido-2-methylpropane sulfonic acid. The alpha-, beta-unsaturated acids useful in this invention are acrylic acid, crotonic acid, methacr~lic acid, itaconic acid, maleic acid, maleic anhydride, fumaric acid ~nd the lihe. The poly-functional alcohols which form the hydroxyalhyl esters 20 iwlude glycol, gl~cerol, propylene gl~col, trimethylene glycol and other polyhydric alhanols, dialkylene glycols of 2 to 12 carbon atoms, pol~alkylene glycols, etc. Pol~alhylene gl~cols are e~ernplified by triPth~lene glycol, tetraethylene glycol, pentaethylene gl~col, he~aeth~lene gl~col and the lihe.
The preferred h~drophilic monomers are the h~dro~yalh~/l esters, specificall~
2S hydroxyeth~l methacrylate (HEMA).
Useful amides of the foregoing acids include diacetone acrylamide and N-mono-substituted diacetone acrylamide. Also useful are the amines of the foregoing acids such as mono- or di-alhylRmino substituents.
A nitrogen containing monomer which may be used in the preparation of 30 the polymers and copolymers of this invention is convenientl~ referred to as N-vin~l lactam which includes (a) N-vin~l lactams per se and ~b) other heteroc~clic N-vinyl monomers. Illustrative of the N-vinyl lactams that are employed in this invention are N-vinyl-2-pyrrolidinone, N-~l-methyl vinyl) p~rrolidinone, N-vinyl-2-piperidone, N-vinyl-2-caprolactam and the like which ~.~7'723S
may be substituted in the lactam ring by one or more lower ulhyl groups such as methyl, ethyl or propyl, e.g., N-vinyl-5-methyl pyrrolidinone, N-vinyl-3,3-dimethyl pyrrolidinone, N-vinyl-5-ethyl pyrrolidinone, N-vinyl-6-methyl piperidone, etc. Illustrative of the other heterocyclic N-vin~l monomers used 5 in preparing the polymers of this invention are N-vinyl imidazole, N-vinyl succinimide, N-vinyl diglycolylimide, N-vinyl glutarimide, N-vinyl-3-morpholinone, N-vinyl-5-methyl-3-morpholinone, etc. The lactams may be effectively employed alone or in admihture with other lactam monomers to give hydrogels having the foregoing desirable characteristics.
The second monomeric component forming the poly mer of this invention is an alpha-, beta-unsaturated car~onyl modified or unmodified amino acid monomer or monomers. This component can be present in varying amounts, desirabl~ in an amount from about 5 ~ to about 27 ~ w/w and, more preferably, about 6 ~ w/w of the total monomers prese7t in the I5 polymeri2ation mihture. The modified or unmodified amino flcid monomers are hydrophilic compounds which contribute significantly to the swelling of the polymer in water and permit higher oh~gen diffusion.
The alpha-, beta-unsaturated carbonyl modifier for the modified amino acids of this invention may be, for ehample, acrylic acid, crotonic acid, ~0 methacr~lic acid, maleic acid, fumaric acid, itaconic acid and their functional derivatives, i.e~, acid chlorides, anh~drides, amides and esters. The more preferred modifiers are methacrylic acid and methacroyl chloride.
An amino acid is an organic acid ~hose molecule contains both a carbo1~yl group ICOOH) and an amino group (NH2) coupled with an alkyl, 25 c~cloalh~l, aryl or heterocyclic structure, the alkyl, cycloalhyl or heteroeyclic structure being free of olefinic unsaturation. The alpha-, beta-carbonyl substituent can be attached to either the amino group or the hydro~ group of the amino acid, dependi~lg on the structure of the amino acid. Additionally, the carbonyl substituent can attach to other reactive groups, if present, in the30 amino acid, e.g., thiol (SH~ or phenolic hydro~yl.
Amino acids useful in the preparation of the modified acids of this invention include, but are not limited to, beta-alanine, ~amma-aminobutyric acid, omega-aminocaproic acid, omega-aminododecanoic acid, beta~ycanoala-nine, epsilon-meth~lhistidine, canavanine, djenkolic acid, l-a~aserine, gamma-. ' :
~27723~;
meth~lene glutamic acid, N-meth~ltyrosine, glycine, alanine~ serine, cystine, cysteine, lanthionine, phenylalanine, tyrosine, diiodot~rosine, tryptophan, histidine, aminobutyric acid, methionine, valine, norvaline, leucine, isoleucine, norleucine, arginine, ornithine, lysine, aspartic acid, glutamic acid, threonine, S hydrohyglutamic acid, proline, hydro~yproline, asparagine, glutamine, desmosine, isodesmosine, 5-h~drosylysine and the lihe. Preferred AminO acids are glycine, glutamic acid, desmosine and isodesmosine.
It should be understood that other, though perhaps less common, amino acids occurring in nature or prepared synthetica]lly, including those shown in lO the ehamples which follow, are within the scope of this invention. Reactive sites on the amino acids can be partially bloched by saturated nonpol~meriz-able subs~ituents provided that one reactive site is substituted by the alpha-, beta-carbonyl substituent.
The polymers used in this invention are cross-linhed by all types of 15 cross-linking compounds used in the prior art, see for instance, U.S. Patent Nos. 3,822,089; 4,152,508; and 4,4~0,919. The cross-linking agent can be employed in varying amounts and desirably in an amount from about 3 to about 30 parts by weight of the total monomers present. Examples of cross-linking agents include polyfunctional derivatives of the previously enumerated a ha-, 20 beta-unsaturated acids, e.g., acrylic acid, methacrylic acid, crotonic acid, itaconic acid, maleic acid, fumaric acid, acrglamide, methacrylamide, multi-vinyl substituted ben~enes, etc. More particularl~ these cross-linhing agents include, but are not limited to, the following: ethylene glycol diacrylate or dimethacrylate, diethylene glycol diacrylate or dimethacryLqte, triethylene 25 glgcol diacrglate or dimethacrylate, tetraethylene gl~col diacrylate or dimethacrylate, polyethylene glycol diacrylate or dimethacrylate, trimethylol-propane triacrylate or trimethacrylate, bisphenol A diacrylate or dimeth-acrylate, ethoxylated bisphenol A diacrylate or dimethacrylate, pentaery-thritol tri- and tetra-acrylate or methacrylate, tetramethylene diacrylate or 30 dimethacrylate, methylene bisacrylamide or methacrylamide, dimethylene bisacrylamide or methacrylamide, N,N'-dihydroxyethylene bisacrylamide or methacrylamide, heY.amethylene bisacrylamide or methacrylamide, decamethylene bisacrylamide or methacrylamide, divinyl benzene, vinyl ~2~7'~23~
methacrylate, allyl methacrylate, etc. A preferred cross-linking agent is allyl methacrylate.
Still other useful cross-linhing agents include 1,3-bis ~-methacrylo~l o~alhyl) tetra disiloxane and similar poly ~organo-siloxane) monorners set 5 forth in U.S. Patent No. 4,l53,6gl. Another group of useful cross-linhing agents are the resonance free di~alkylene tertiary amine) cyclic compounds, e.g., N,N'~ivinyl ethylene urea, as disclosed in U.~. Patent No. ~,436,887.
Yet another group are di- or polyvinyl ethers of di-- or polyvalent alcohols such as ethylene glycol divinyl ether.
The formulatior~ of the instant invention also contains a lower alhyl (Cl-C~), polar solvent, preferably volatile, demonstrating high water solu~ilityparameters such as a lower alhyl ~CI-Cd,) alcohol, an unmodified or modified hetone and the like for controlling the viscosity of the polymer. Suitable solYents may also include mi~-tures of modified and unmodified hetones in any proportions and mi~tures of a lower alh~l ~CI~Cg) alcohol and water in any proportions. E~amples o~ solvents are methanol, ethanol, propanol, butanol, isopropanol, acetone, methyl eth~l hetone, h~dro~yacetone, etc. Typically, equal parts of solvent and linear, poly meri~ed poly mer are used in the preparation of the formulation. However, different amounts of the solvent 20 may be used with the polymer though generally less conveniently. When the process of this invention is followed, the residue of the solvent remains in theformvlation in varying amounts depending upon reaction conditions such as time and temperature. Preferabl~ trace amounts of the residue are present for ophthalmic use and higher amounts are present for transdermal use.
Optionall~, a chain regulator or chain transfer a~ent may be added if a particular monomerffolvent combination requires ;t. ~or e~ample, certain combinations containing solvents such as butanol may require large quantities of butanol which may not be desirable in the product. If a chain regulator is added, a smaller amount of butanol may be used.
3~ The term "chain regulator" refers to any chemical that controls the molecular weight of the pol~mer during polymerization. A chain regulator may be optionally emploS~ed in var~ing amounts and desirably in an amount from about 0.01 4t w/w to about 0.5 ~ w/w. Ehamples of chain regulators include, but are not limited to, dodecanethiol, isopropyl mercaptan, 7~3S
decanethiol and the lihe. A particularly preferred chain regulator is dodecanethiol.
Por some applications the polymeri~ates formed from the above hydro-philic monomer(s), modified or unmodified amino acid monomer~s), cross-5 linking agent(s), a lower alhyl (Cl~Cg) alcohol snd an optional chain regulatormay lack the desired physical handling properties. It is another aspect of this invention in such circumstances to incorporate one or more hydrophobic monomers in the above polymers in varging amounts, desirably from about 8 t to about 20~ w/w of the total monomers present. nqore preferably the 10 hydrophobic monomer would be present in an amount of about lO ~c w/w of the total monomers present. Among other things, the hydrophobic monomers are useful as modulus modifiers.
The modulus modifier may be, Ior eY.ample, cycloalhyl ester, tertiary-but~l styrene, polycyclic acrylate or rnethacrylate, and the lihe as well as 15 mi~tures thereof. More particularly the polycyclic modifiers mag be isobornylacr~late, isobornyl methacrylate, dic~clopentanedienyl acrylate, dic~clopen-tanedien~l methacrylate, adamantyl acrylate, adamantyl methacryl~te, isopinocamphyl acr~late, isopinocamph~l methacrylate, etc. and mixtures thereof. The cycloalhyl ester modifier is of formula I below. Illl~strative of 20 these cycloalhyl modifiers are menthyl methacrylate, menthyl acrylate, tertiarybut~l cyclohe~yl methacr~late, isohe~l cyclopentyl acr~late, meth~lisopentyl cyclooctgl acrylate snd the like.
- ~ O -- C ~ ~ Y ~2 ~ ~ ~
S I ) J ~ E
Z~ D
~(C~2) n~
wherein: ~
30 D is branched or normal alh~l of 3 to 6 carbon atoms E is H or CH3 Z is H or CH3 - l u -~2'7~Z3~
n is an integer from 3 to 8.
In addition to the modulus modifiers other well hnown hydrophobic monomers ma~ be used in the formulation of the pol~rners and copolymers of this invention to further tailor the properties to the particular application.
5 The h~drophobic monomers of this invention include monomers which contain at least one silicon or fluorine atom as a part of its composition. Hydrophobic monomers include alhyl, c~clo-alhyl and aryl acrylates and methacr~lates as well as mono- or disubstituted itaconates, styrene and its derivatives, acr~lonitrile, vin~l esters such as vinyl acetate or vin~l pentacet~l gluconate,10 vin~l ethers such as vinyl butyl ether, allyl esters such as all~l acetate, propionate or butyrate, fluorine containing monomers such as octafluoropenty1 methacrylate and silicon containing monomers, e.g., 1,1,1-tris ;trimethoky-silox~) -3-methacrylox~-prop~lsilane or heptameth~ltrisilo~-anyl ethyl acrylate The monomeric mixtures, comprising the hydrophilic mondmer(s), the 15 modified or unmodified amino acid monomer(s), the optional hydrophobic monomer(s), the cross-linhing agent, the lower alhyl (Cl-C4) alcohol and ~he optional chain regulator are generally clear, colorless liguids of vary ing viscosity. These monomer mixtures are polymeri~ed but not cross-linhed using ultraviolet light at room temperature. According to the process of this 20 invention, the medicinal agent dissolves in this linear, pol~meri2ed pol~mer that can then be cross-linhed b~ ultraviolet light and/or heat. Before cross-linhing takes place, the linear polymer is characteri~ed by being soluble in methanol and isopropanol. After cross-linking, an insoluble pol~mer is formed.
As catal~sts for carrying out the pol~meri~ation, there ma~ be 25 employed a free radical catalyst (initiator) in varying amounts and typically in the range of about O.O5t to 3~ w/w of the po1ymeri2able monomer mi~ture.
The preferred amount of catalyst is 0.1~c to ~.5q: w/w OI the total monomers present. Usually, the catalyst is added initially to the monomers and then the pol~meri2ation procedure is completed. The free radical type initiators 30 suitable for this invention include peroxides, a20 compounds, ohidation-reduction systems and similar initiatcrs described in the literature~ Typical catalysts include ben201n methyl ether, tertiary-butyl-peroctoate, benzo~l peroxide, isopropyl percarbonate, meth~l ethyl hetone peroxide, cumene ~;~7723~
hydroperoxide, dicum~l perohide, bis(isopropyl) perohydicarbonate, 2,2'-azobis[isobutyronitrilel, acetyl pero~ide, lauroyl peroxide, decanoyl peroxide, 2t2'-azobis 1 2,4-dimethylvaleronitrile~, phthalic perol-ide, diethok~acetophe-none, tertiary~utyl peroh~pivalate and the lihe. Thermal catalysts, visible 5 light or irradiation, e.g., by ultraviolet light or gamma rays, also can be employed to catal~ze the polymeri2ation. Polymerization can be done at 20 to 150C, usually ~0 to 90C. Prior to adding a mledicament or to cross-linhing the polymer, a prepolymerization of the monomer mi1- may be achieved at room temperature, usuall~ 20 to ~8C, to create a linear, polymeri~ed 10 pol~mer. Cross-linhing ma~ be done using a suitable amount of heat, typically65 to 75C. The choice of cata1~st obviousl~ dlepends upon the temperature desired for the reaction.
Water soluble diluents may be used with the foregoing polymers to modify the physical properties of these pol~ mers. More particularly, the 15 diluents may be advantageous in improving machinability and swell character-istics of the pol~mer. Typically, the amount of diluent will be less than 50 weight percent of the total monomers emplo~ed and preferably not more than 30 weight percent. In a particular polymer system, the limiting amount of diluent is the solubility of the diluent in the monomer system. Thus, there 20 should be no phase separation between diluent and starting monomer mi~ture.
AdditionaUy, el-cessive amounts of diluent will result in collapse of the cell structure of the finished biomedical devices when the device is h~drated, i.e., replacement of diluent by water~ The maximum amount of diluent is readil~
ascertained b~ swelling the diluent free pol~mer in the proposed diluent and 25 measuring the degree of swell. Comparable results are obtained when using solvent soluble diluents wherein the solvent does not affect the lens polymer.
Suitable diluents include ethylene gl~col, gl~cerin, liguid polyethylene glycols, butanol, butanol/water mixtures, ethylene oxide/prowlene o~.ide bloch copolgmers having a molecular weight from 1,000 to 5,ûO0, linear poly(vinyl 30 pyrrolidinone) having a molecular weight from 500 to 10,000, low molecular weight linear poly(hydro~yethyl methacrylate), gl~col esters of lactic acid, formamide, dimethyl formamide, dimeth~l sulfoxide and the lihe. In the finished biomedical device, it will be necessary to replace an~ diluent with an agueous solution. With respect to contact lenses, the final water content of . . .
~ ~r~
the polymeric composition typicall~ ranges from about 25~ to about 70~ w/w.
The contact lens should, of course, contain a physiological saline solution as the aqueous medium.
Using methods well hnown in the art, the sustained-release formulation of this invention can be formed into a variety of shapes depending upon the end use and desired results to be obtained 1therefrom. ~or ophthalmic purposes, the poly meric hydrogel could have an~ form to maintain direct contact with the e~e. It is not necessar~ to cover the entire cornea if the dosage form is merely used to instill a continuous flow of an ophthalmic drug 10 in the eye. If the h~drogel will also be used to corre--t vision, then it m~y be desirable to cast the polymer on an optical mold.
By way of e~ample, the mihture of hydrophilic monomer(s), modified or unmodified amino acid monomerls), cross-linhing agent, free radical initiator and optional hydrophobic monomer(s) described above is prepared. If àesir-15 able, a chain regulator is added to this mi~-ture. Then a lower alhyl (Cl-C4)alcohol is added. A two-stage process is carried out by forming a linear, poly meri2ed poly mer b~ ultraviolet light at room ~emperature and cross-linking the polymer b~ subseguent application of heat together with ultraviolet light if needed.
This invention contemplates a process for preparing the sustained-release poly meric hydrogel dosage form whereby the medicinal agent is retained by the poly meric matri~ and, upon tissue contact, is gradually released into the tissue. The medicinal agent may be dissolved directly into the linear, uncross-linked polymer. The drug becomes intimate1y mil-ed in the 25 polymeric matrix rflther than remaining as particulate matter. Subsequent cross-linhing prevents co~ol~meri2ation of the drug with the pol~mer allowing for greater recovery of the drug upon tissue contact. The drug would release slowly into the tissue for 1OCQ1 or systemic effect over prolonged time intervals at lower concentrations thereb~ eliminating or reducing side effects.
30 The amount of ti~e drug used in the preparation of the dosage forms will varydepending upon the physicochemical properties of the selected drug and the therapeutic effect desired ~o be achieved. l~picall~, the drug is added on a eguivalenc~ basis, that is, an equivalent for eguivalent basis of drug to the .
- ': ~ . ' : ' .
.
~ :, linear, polymeri~ed polymer. Although a stoichiometric number of equivalents of drug and the linear, polymeri2ed polymer is preferred, other amounts can also be used. As an e~.ample of pilocarpine h~drochloride, varying concentrations of the compound may be employed, desirably an amount from 5 about 5~ to about 15~ w/w, of pilocarpine hydrochloride to the weight of ~he linear polymer, and preferably 9.14 w/w, for incorporation in the dosage form.
The polymeric composition of the instant invention provides appreciable time release of the medicament. The release rate of a drug from the polymeric matria varies with cross-linhing density and type of polyrner barrier 10 system. Additionally, the release rate depends upon the viscosity of the linear, uncross-linhed polymer which is controlled by the addition of a polur, volatile solvent such as a lower alhyl (Cl~Cg) alcohol.
To quantify the release rates, lenses with and without drug can be placed in a known guantity of release media ~distilled water or buffered saline)5 and stirred with a magnetic stirrer. At various times the lenses can be transferred to fresh media and the absorbance of the previous media can be determined by ultraviolet spectroscopy. The absorbance of the media containing drugged lenses is reduced by the absorbance of the media contain-ing undrugged lenses. Use of a calibration curve relating absorbance to 20 concentration allows for a determination of the concentration of the drug.
The calibration curve is developed by measuring the absorbance of hnown concentrations of the drug in the release media. As the concentrations !ug/ml) of the drug and the volume ~ml) of release media are hnown, the amount of the released drug can be calcula~ed ~ug). This value divided by the time of 25 e~posure to the media gives the release rate in,llg/hr which is plotted against time.
The contact lenses made from the polymer utili~,ed in the instant invention are ox~gen permeable. A critical ohygen tension and flul. under A
lens should be about 1~ mm Hg and 2,ul/(cmghr.) respectively below which 30 corneal swelling occurs, see Polse and Decker, Investigative_Ophthalmolog~
and Visual Science, 18:t88 11979). In order to meet these requirements, the lens material must have adeguate o~ygen permeability. These more preferred contact lenses have an o~ygen permeability of at least about 241-t0-1 ~
cm3cm/lsec.cm2mmHg), are hydrolytically stable, biologically inert and ~2t~7~3~
transparent. In comparison, the well-hnown COntACt lens polymer polyhydrok~-ethyl methacr~late has an o~-ygen permeability value of about one-third of the polymers of this invention.
Additionally, these lenses are h~drolytically st~ble, meaning that when 5 the cont~ct lenses are placed into an agueous solution (e.g., on the eye) or during the disinfecting step (i.e., water plus heat), the lenses will not change in chemical composition. That is, the~ will not hydroly~e. On heating in boiling water for 120 hours, the typical pol~mer of this invention experiences a water content loss of 3~ or less. The most preferred lenses/polymers useful in this 10 invention have a stable water content that undergoes less than 1~ change.
Thus, the polymers and copol~ ners disclosed herein can be boiled and/or autoclaved in water without being damaged whereby sterilizQtion may be achieved. In addieion, sterilization can be achieved by ~ irradiation, ultraviolet light irradiation and eth~lene oxide e~posure.
The pol~mers and copolymers employed in this invention bei~3g soft yet resilient and hard to tear are well suited for preparing biomedical devices, including contact lenses, which have the ability to release medications from the pol~meric matrih over a prolonged period of time. It is weU hnown that the wearer of soft contact lenses will have an unavoidable amount of handling 20 of the lenses. Part of the cleaning and rinsing procedure is to rub each lens and tearing has been a concern in prior art lenses. The polymers and copol~mers used in the present invention have a tear initiation strength (ASTM
D-1938) of up to 5 g/mm of thichness.
An article formed from the disclosed polymers and copolymers may be 25 used to administer medications to mammals where an article compatible with living tissue or with the mucous membranes is desired. The term "biomedical devices7' means the materials disclosed herein have nonto~ic, nonirritating ph~siochemical properties rendering them suitable for prolon~ed contact with living tissue, blood and the mucous membranes. It is hnown that blood, for 30 e~ample, is rapidl~ damaged in contact with artificial surfaces. The design of a s~nthetic surface which is antithrombogenic and nonhemolytic to blood is necessar~ for drug edministering devices used with blood, especially an implanted or transdermal device. The polymers and copolymers emplo~ed for the purposes of the instant invention are compatible with living tissue.
- ' ' ' The instant invention provides a novel sustained-release poly meric h~drogel dosage form useful for topical, systemic or transdermal administra-tion of a medicinal agent comprising the above-described polymeric matrix in association with a therapeutically effective amount of the medicinal agent.
5 When prepared according to the novel process OI this invention, the polymeric matri1. permits the active ingredient to be subseguently released at a gradual, carefully controlled rate prolonging the time release period. Further, this invention concerns a method of administering a therapeutically effective amount of a medicinal agent over an extended pleriod of time to Q mammal in 10 need of the medicinal agent which comprises contacting a tissue of said mammal with the sustained-release polymeric hydrogel dosage form for a sufficient amount of time to achieve a constant therapeutic effect. In contrast to normal disintegration time, the sustained-release administration of medicaments enhances therapeutic effectiveness and decreases many undesir-15 able side effects by maintaining constant tissue and blood levels.
The po~ meric hydrogel dosage form can be used in preparingbiomedical devices that upon surgical implant will provide sustained-release activity of the active ingredient. Depending on the location of the implant, the therapeutic effect may be local or systemic. The dosage form can also 20 provide for the oral or topical (i.e., locali~ed activity on the shin) controlled-release administration of medicaments. Additionally, the dosage form can be utili~ed for the transdermal controlled-release administration of medicaments, i.e., the device is retained in contact with the skin for transdermal absorptionof the medicament into the blood for systemic effect. Contact with the skin 25 ma~ be achieved by any means we~l-known in the art such as ~ incorporating an adhesive in or on the device, adhering the device within or onto a bandage-type al ticle, etc.
Further, the dosage form c~n be useful for the ophthalmic route of adminis.ering medicinal agents for either local or systemic therapeutic effect.
30 The term "ophthalmic administration of a systemic medicament" defines the administration of a medicinal agent to a mammal ~ the ophthalrnic route whereby the medicinal agent acts therapeutically to create a systemic effect.
For ophthalmic administration of a medicament to produce local or systemic activit~, the polymeric composition can be molded into any convenient shape ' . - ~
. . ~
~277Z3~
for e~e contact. If correcting vision is not necessary, the dosage form does not have to cover the entire cornea. Alternatively, the pol~meric hydrogel can be shaped into contact lenses on optical molds if it is desirable to correctvision in addition to administer ophthalmic medicaments.
The length of time for contac~ing the poly meric h~drogel device containing a medicament with a tissue ~f a mammal depends upon the individual circumstances of each c~se. A sufficient amount of time to achieve a constant therapeutic effect varies in accordance with the optimum thera-peutic effect desired. The duration of therap~ is, of course, contingent upon 10 the disease or medical problem being treated or palliated. Lihewise, the therapeutically ef~ective amount of tl)e specific medicinal agent is determined by therap~ reguirements and the bioph~sical proper~ies of the active compound. For eaample, with respect to contact lenses, the invention contemplates dail~ wear or e~tended wear, typically, up to a month. To traat 15 sn e~e infection, it would be desirable to maintain the contact lens ;containing an antibiotic or an antiviral agent on the eye for one to two weehs. ~n the other hand, to treat glaucoma, it would be desirable to wear the lens containing an agent for reducing intraocular pressure for the ma1-imum time that extended wear eontact lenses can remain in the eS~e.
The term "dosage form" refers to physically discrete un;ts suitable as unitary dosage for mammals, each unit containing a predetermined quantity of ac~ive component calculated to produce the desired therapeutic effect. The novel sustained-release dosage form of this invention is indicated b~ the ph~sical or chemical characteristics of the active component and the 25 particular therapeutic effect to be achieved.
The term "a medicinal agent" means a substance used in treating or ameliorating a disease or medical condition. For purposes OI this invention, "a medicinal agent" refers to drugs which would have the eapacit~ to be bound to the amino acid moiet~ of the polymeric h~drogel. That is, any drug or its salt 3~ with polar characteristics that interacts with amino acids in 8 ~avorable wa~could be used in the present invention. Eaamples of medicinal agents include, but are not limited to, antibiotics, antivirals, anti-inflammatories, steroids, peptides, pol~peptides, cardiotonics, antih~pertensives, antiallergics, alpha-and beta-adrenergic bloching agents, anticataract agents, ophthalmic , ~77~
medicaments, ophthalmic lubricating agents, ophthalmic topical or regional anesthetic agents, etc. The ophthalmic medicaments or other medicinal agents encompass such drugs as pilocarpine, idoxuridine, carbachol, bethanechol, timolol, tetracycline, epinephrine, phenylephrine, eserine, 5 phospholine, demecarium, cyclopentolate, homatropine, scopolamine, nitroglycerin, chlortetracycline, bacitracin, neomycin, polymy~in, gramicidin, oxytetracycline, chloramphenicol, gentamycin, penicillin, erythromycin, sulfacetamide, polymyxin B, tobramycin, isofluorophate, fluoromethalone, de~amethasone, hydrocortisone, fluorocinolone, medrysone, prednisolone, 10 methyl prednisolone, betamethasone, triamcinolone, interferon, cromolyn, all-tr -retinoic acid ~Vitamin A), the nonto~ic, pharmaceutically acceptable salts thereof and the lihe. The category of ophthalmic lubricating agents refers to those agents capable of inducing natural lacrimation or creating artificial lacrimation and includes, for e~ample, polyvin~l alcohol, cellulose 15 polymers such as hydrohypropyl methyl cellulose, a polylactam such as polyvinylpyrrolidinone and other tear inducers or substitutes. The topical or regional anesthetic agents, which may be useful during ophthalmic surgery or other ophthalmic procedures, include lidocaine, cocaine, beno~.inate, dibucaine, proparacaine, tetracaine, etidocaine, procaine, hexylcaine, 20 bupivacaine, mepivacaine, prilocaine, chloroprocaine, etc.
The term "pharmaceutically acceptable salt" refers to those salts of the parent compound which do not significantl~ or adversely affect the pharma-ceutical properties le.~., toxicity, efficacy, etc.) of the parent compound. Thesalts of the present invention which are pharmaceutically acceptable include, ~5 for example, chloride, iodide, bromide, h~drochloride, acetate, nitrate, stearate, phosphate, sulfate, etc. It is desirable to use the appropriate salt form of the active ingredient which would increase the water solubility or polar characteristics of the base compound.
In addition to the medical uses, the above described polymeric hydrogel 30 may be found useful with veterinary products and agricultural chemicals such as pesticides, herbicides and the lihe. For example, a pesticide incorporated into the polymer may be mi~ed with fertili~ers. On spraying, the alcohol evaporates leaving a filn~ which could be made biodegradable.
The following examples demonstrate certain aspects of the present 35 invention. However, it is to be understood that these examples are for ~LZ~7~3~5 illustrative purposes onl~ and do not purport to be wholly definitive as to conditions and scope of this invention. All parts and percents referred to herein are on n weight basis and all temperatures are expressed in degrees Celsius unless otherwise specified. It also should be appreciated that when 5 t~pical reaction conditions ~e.g., temperature, reaction times) have been given, the conditions which are both above and below these specified ranges can also be used, though generall~ less convenientlg.
A further understanding of the invention may be obtainsd from the following nonlimiting examples. These e~amples were conducted at room 10 temperature (about 23C to about 28C) and at atmlospheric pressure.
Esample 1 Preparation of a H~drogel Pol~mer Containing Pilocarpine Hgdrochloride A mihture is prepared b~ combining 7g.5 g of 2-h~dro~yethyl meth-5 acr~late (HEMA) containing 0.12~ of ethylene glycol dimbthacrylatetEGDMA), 1~ g of isoborn~l methacrylate ~IBOMA), 8 g of methacroyl glycine (MG), 2.5 g of ben~oin methyl ether (BME) and 0.1 g of 2, ~'-a~obisl isobu-tyronitrile ~ . To the mihture is added 5 g of allyl methacrylate. To 5 g of themixture is added 5 g of methanol. This mixture is then purged with nitrogen 20 and polymeriæation is performed with stirring under ultra~iolet light (UV) at room temper~ture for 2 hours. When a hone~-lihe consistenc~ develops, 0.205 g of pilocarpine hydrochloride is added to 4 g of the linear polymer forming a clear solution. The solution is cross-linked with a subseguent exposure to UY for 30 minutes at room temperature and then ~o UV for 30 25 minutes at 70C.
E~.ample 2 Preparation of a H~drogel Polymer Containing Pilocar~ne H~drochloride The procedure of Ehample t is repeated to prepare the hydrogel 30 polymer with the additional step of adding 0.01 g of dodecanethiol after the a11yl methacrylate is added to the mikture.
.
, - l9 -E~ample 3 Preparation of a Hydrogel Polymer Containin~ Pilocerpine H~drochloride The procedure of Example t is repeated to prepare the hydrogel polymer with the additional step of adding 0.02 g of dodecanethiol after the Qllyl methacr~late is added to the mixture.
Ehample ~
Preparation of a Hydrogel Polymer Containin~ Pi~chloride The procedure of E~-ample 1 is repeated to prepare the hydrogel polymer with the additional step of adding 0.25 g of dodecanethiol after the allyl methacrylate is added to the mihture.
Example 5 Preparation of a Hydrogel Polymer Containing Pilocarpine H~drochloride The procedure of Eaample I is repeated to prepare the hydrogel polymer with the additional step of adding û.5 g of dodecanethiol after the allyl methacryLqte is added to the mi~ture.
Ehample 6 Preparation of a H~drogel Polymer Containing Nitrogl~cerin The h~drogel polymer of this example is prepared according to the procedure of Ehample I e~cept that 0.025 g of nitroglycerin is substituted for the pilocarpine hydrochloride.
ExamPle 7 Preparation of a H~drogel Polymer Containing Scopolamine The hydrogel polymer of this ex~mple is prepared according to the procedure of E~ample 1 except that 0.2 g of scopolamine is substituted for the 30 pilocarpine hydrochloride.
In the foregoing there has been provided a detailed description of preferred embodiments of the present invention for the purpose of illustration and not limitation. It is to be understood that all other modifications, 35 ramifications and eguivalents obvious to those having skiU in the art based on this disclosure are intended to be within the scope of the invention as claimed.
- . .:
. .~ . . ~
.~' - '- :
. , .';- . ' : , - ' : . . ' '-: " - : .
.
~- - '' ' :
Claims (17)
1. A sustained-release polymeric hydrogel dosage form useful for topical, systemic or transdermal administration of a medicinal agent comprising a cross-linked, polymerized hydrophilic polymer including an amino acid moiety in the polymer, in conjunction with a lower alkyl (C1-C4) polar solvent and said medicinal agent in a therapeutically effective amount.
2. The sustained-release dosage form of claim 1, wherein the polymer includes a hydrophobic component.
3. The sustained-release dosage form of claim 1 or 2 wherein the amino acid moiety is derived from an aliphatic monocarboxylic acid, an aliphatic dicarboxylic acid, an aromatic dicarboxylic acid, an aromatic tricarboxylic acid or an aromatic tetracarboxylic acid.
4. The sustained-release dosage form of claim 1 or 2 wherein the amino acid moiety is derived from methacroyl glycine, methacroyl glutamate, methacroyl desmosine or methacroyl isodesmosine.
5. The sustained-release dosage form of claim 1 or 2 wherein the polar solvent is a lower alkyl (C1-C4) alcohol, an unmodified ketone, a modified ketone, a mixture of a lower alkyl (C1-C4) alcohol and water in any proportion or a mixture of an unmodified ketone and a modified ketone in any proportion.
6. The sustained-release dosage form of claim 1 or 2 wherein said medicinal agent is an antibiotic, an antiviral, an anti-inflammatory, a steroid, a peptide, a polypeptide, a cardiotonic, an antihypertensive, an antiallergic, an alpha-adrenergic blocking agent, a beta-adrenergic blocking agent, an anticataract agent, an ophthalmic medicament, an ophthalmic lubricating agent or an ophthalmic anesthetic agent.
7. The sustained-release dosage form of claim 1 or 2, wherein said medicinal agent is selected from the group consisting of pilocarpine, idoxuridine, carbachol, bethanechol, timolol, tetracycline, epinephrine, phenylephrine, eserine, phospholine, demecarium, cyclopentolate; homatropine, scopolamine, nitroglycerin, chlortetratcycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, penicillin, erythromycin, sulfacetamide, polymyxin B, tobramycin, isofluorophate, fluoromethalone, dexamethasone, hydrocortisone, fluorocinolone, medrysone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, interferon, cromolyn, all-trans-retinoic acid and a nontoxic, pharmaceutically acceptable salt thereof.
8. The sustained-release dosage form of claim 1 or 2, wherein said medicinal agent is an ophthalmic lubricating agent selected from the group consisting of polyvinyl alcohol, a cellulose polymer and a polylactam.
9. The sustained-release dosage form of claim 1 or 2, wherein said medicinal agent is an ophthalmic anesthetic agent.
10. The sustained-release dosage form of claim 1 or 2, wherein said dosage form is molded as a contact lens or ocular insert for ophthalmic administration of a systemic medicament, an ophthalmic medicament or an ophthalmic lubricating agent.
11. The sustained-release dosage form of claim 1 or 2, wherein said dosage form is molded as a contact lens for ophthalmic administration of a systemic medicament, an ophthalmic medicament or an ophthalmic lubricating agent and retains the ability to correct vision.
12. The sustained-release dosage form of claim 2 wherein a polymeric hydrogel is prepared from a polymerizable hydrophilic monomer present in the amount of about 50% to about 90% w/w, an amino acid monomer present in the amount of about 5% to about 27% w/w, a cross-linking agent present in the amount of about 3% to about 30% w/w and a hydrophobic monomer present in the amount of about 8% to about 20% w/w, the weight percent being based on the total weight of the polymeric hydrogel.
13. A process for the preparation of the sustained-release dosage form of claim 1 which comprises mixing a hydrophilic monomer, am amino acid monomer, a cross-linking agent and a lower alkyl (C1-C4) polar solvent polymerizing at room temperature, adding a medicinal agent and cross-linking.
14. A process for the preparation of the sustained-release dosage form of claim 2 which comprises mixing a hydrophilic monomer, an amino acid monomer, a cross-linking agent and a lower alkyl (C1-C4) polar solvent, polymerizing at room temperature, adding a medicinal agent and cross-linking.
15. The process of claim 13 or 14 wherein a catalyst is used.
16. The process of claim 13 or 14 wherein a chain regulator is added.
17. The process of claim 13 or 14 wherein a catalyst is used and a chain regulator is added.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US766,734 | 1985-08-16 | ||
| US06/766,734 US4713244A (en) | 1985-08-16 | 1985-08-16 | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1277235C true CA1277235C (en) | 1990-12-04 |
Family
ID=25077355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000515031A Expired - Lifetime CA1277235C (en) | 1985-08-16 | 1986-07-31 | Sustained-release formulation containing an amino acid polymer with alower alkyl (c -c ), polar solvent |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4713244A (en) |
| EP (1) | EP0212959B1 (en) |
| JP (1) | JPS6296417A (en) |
| CA (1) | CA1277235C (en) |
| DE (1) | DE3687868T2 (en) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| CS263203B1 (en) * | 1986-07-22 | 1989-04-14 | Sulc Jiri | Soft intraocular lenses |
| US5032109A (en) * | 1987-02-10 | 1991-07-16 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US4878892A (en) * | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US5110600A (en) * | 1988-01-25 | 1992-05-05 | The Regents Of The University Of California | Method of treating viral infections with amino acid analogs |
| US5192316A (en) * | 1988-02-16 | 1993-03-09 | Allergan, Inc. | Ocular device |
| US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
| US5760261A (en) * | 1990-02-28 | 1998-06-02 | Guttag; Alvin | Higher fatty acid derivatives of salicylic acid and salts thereof |
| US5173302A (en) * | 1990-09-28 | 1992-12-22 | Medtronic, Inc. | Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs |
| ES2149178T3 (en) * | 1991-08-16 | 2000-11-01 | Miles A Galin | EYE IMPLANT FOR THE FRONT REFRACTIVE CAMERA, COATED WITH A MEDICATION. |
| AU3469893A (en) * | 1992-01-15 | 1993-08-03 | Allergan, Inc. | Hydrogel compositions and structures made from same |
| US5596007A (en) * | 1992-05-18 | 1997-01-21 | Pharmaco Behavioral Associates, Inc. | Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine |
| US5643928A (en) * | 1992-10-21 | 1997-07-01 | Pharmaco Behavioral Associates, Inc. | Human body weight management |
| US5612357A (en) * | 1992-05-18 | 1997-03-18 | Pharmaco Behavioral Associates, Inc. | Use of cotinine to assist in the cessation of tobacco smoking |
| US5869505A (en) * | 1993-02-02 | 1999-02-09 | Keenan; Robert M. | Nicotine metabolites and nicotine dependence |
| US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
| US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| CA2144407C (en) * | 1992-09-10 | 2000-05-30 | Charles B. Berde | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| US6162456A (en) * | 1992-09-24 | 2000-12-19 | Ortho-Mcneil Pharmaceutical, Inc. | Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers |
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| US5573774A (en) * | 1993-02-02 | 1996-11-12 | Keenan; Robert M. | Nicotine metabolites, nicotine dependence and human body weight |
| DE4313928C2 (en) * | 1993-04-28 | 1996-09-19 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for the controlled delivery of pilocarpine to the skin, process for its production and its use |
| US5505952A (en) * | 1994-04-19 | 1996-04-09 | United States Surgical Corporation | Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom |
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| NZ311474A (en) * | 1995-06-09 | 1997-09-22 | Euro Celtique Sa | Formulations for providing prolonged local anesthesia |
| AU6286796A (en) * | 1995-07-12 | 1997-02-10 | Corning Incorporated | Novel photochromic organic materials |
| US5723131A (en) | 1995-12-28 | 1998-03-03 | Johnson & Johnson Vision Products, Inc. | Contact lens containing a leachable absorbed material |
| JPH11511763A (en) | 1996-06-24 | 1999-10-12 | ユーロ―セルティーク，エス．エイ． | How to provide safe local anesthesia |
| US6046187A (en) | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
| US6476103B1 (en) * | 1996-10-11 | 2002-11-05 | Corning Incorporated | Photochromic organic material, its manufacture and the photochromic articles containing it |
| AUPO379596A0 (en) * | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
| EP1009390A4 (en) | 1997-07-02 | 2004-05-06 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6346536B1 (en) | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6395749B1 (en) | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
| US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
| US6410045B1 (en) | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
| US20020197300A1 (en) * | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| TWI279401B (en) * | 1999-08-31 | 2007-04-21 | Incyte San Diego Inc | Heterocyclic derivatives for the treatment of diabetes and other diseases |
| US6315987B1 (en) * | 2000-05-10 | 2001-11-13 | Isp Investments Inc. | Polymeric delivery and release systems for oral care actives |
| US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| US6348475B1 (en) | 2000-06-01 | 2002-02-19 | Guilford Pharmaceuticals Inc. | Methods, compounds and compositions for treating gout |
| US20040151755A1 (en) * | 2000-12-21 | 2004-08-05 | Osman Rathore | Antimicrobial lenses displaying extended efficacy, processes to prepare them and methods of their use |
| EA200300982A1 (en) | 2001-03-07 | 2004-12-30 | Инсайт Сан Диего, Инк. | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES |
| CA2473156A1 (en) * | 2001-03-08 | 2002-09-19 | Incyte San Diego, Inc. | Rxr activating molecules |
| CA2340824A1 (en) * | 2001-03-14 | 2002-09-14 | Ibm Canada Limited-Ibm Canada Limitee | Method and system for application behavior analysis |
| US20030083357A1 (en) * | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| EP1446099B1 (en) * | 2001-11-14 | 2009-07-15 | Durect Corporation | Injectable depot composition |
| KR20040058101A (en) | 2001-11-14 | 2004-07-03 | 알자 코포레이션 | Catheter injectable depot compositions and uses thereof |
| AU2002352706A1 (en) | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| WO2004011054A2 (en) | 2002-07-31 | 2004-02-05 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
| DE60226282T2 (en) | 2002-07-31 | 2009-09-17 | Alza Corp., Mountain View | INJECTABLE DEPOT COMPOSITIONS AND THEIR USE |
| US7795203B2 (en) * | 2002-09-30 | 2010-09-14 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004066952A2 (en) * | 2003-01-29 | 2004-08-12 | Incyte Corporation | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
| KR20060036896A (en) * | 2003-04-18 | 2006-05-02 | 인사이트 산 디에고 인코포레이티드 | Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| WO2005007714A1 (en) * | 2003-07-18 | 2005-01-27 | Japan Exlan Company Limited | Polymer sustainedly releasing amino acid derivative, cosmetic and fiber construct containing the polymer, method of producing the same and method of regenerating the same |
| PT1682537E (en) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Modulators of cellular adhesion |
| WO2006017275A1 (en) | 2004-07-13 | 2006-02-16 | The University Of Tennessee Research Foundation | Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts |
| JP2008519847A (en) * | 2004-11-10 | 2008-06-12 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | How to treat movement disorders |
| NZ554783A (en) * | 2004-11-15 | 2010-12-24 | Ceptyr Inc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| US9804295B2 (en) † | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| LT2444079T (en) | 2005-05-17 | 2017-03-27 | Sarcode Bioscience Inc. | Compositions and Methods for Treatment of Eye Disorders |
| EP3081215B9 (en) | 2005-05-23 | 2020-08-19 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
| DE102006052342B4 (en) * | 2006-11-07 | 2015-08-20 | Wöhlk-Contact-Linsen GmbH | Contact lens material |
| US8071119B2 (en) * | 2007-05-14 | 2011-12-06 | Sustained Nano Systems Llc | Controlled release implantable dispensing device and method |
| US20090148498A1 (en) * | 2007-05-14 | 2009-06-11 | Sustained Nano Systems Llc | Controlled release implantable dispensing device and method |
| WO2008143906A2 (en) * | 2007-05-14 | 2008-11-27 | Sustained Nano Systems Llc | Hypercompressed particles for controlled release of ophthalmic medications |
| EA020466B1 (en) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX2010004281A (en) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Compositions and methods for treatment of diabetic retinopathy. |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | Delivery of lfa-1 antagonists to the gastrointestinal system |
| JP2011522828A (en) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US9732324B2 (en) | 2008-10-23 | 2017-08-15 | Cornell University | Anti-viral method |
| US10201548B2 (en) * | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| US10980818B2 (en) | 2009-03-06 | 2021-04-20 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2719512A1 (en) | 2010-11-01 | 2012-05-01 | Stiefel Research Australia Pty Ltd | Polymeric topical compositions |
| MX362218B (en) | 2011-05-04 | 2019-01-09 | Balance Therapeutics Inc | Pentylenetetrazole derivatives. |
| US20130004651A1 (en) * | 2011-07-01 | 2013-01-03 | Patty Fu-Giles | Sustained drug release from body implants using nanoparticle-embedded polymeric coating materials |
| EP3715345B1 (en) | 2012-07-25 | 2024-04-10 | Novartis AG | Preparation of lfa-1 inhibitor |
| EP2912121B1 (en) | 2012-10-29 | 2019-09-25 | Ariste Medical, LLC | Polymer coating compositions and coated products |
| AU2014218599C1 (en) | 2013-02-25 | 2018-09-06 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists for use in colonic cleansing |
| JP2016514670A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase receptor agonists in combination with other drugs |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2926691A1 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
| EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| AU2015249769A1 (en) | 2014-04-22 | 2016-11-10 | Ariste Medical, Llc. | Methods and processes for application of drug delivery polymeric coatings |
| EP3291886A1 (en) | 2015-05-04 | 2018-03-14 | Ecole Polytechnique Federale de Lausanne (EPFL) | Ophthalmic contact lens with a compressible affinity matrix |
| CN108884130B (en) | 2016-01-11 | 2022-09-13 | 博士医疗爱尔兰有限公司 | Formulations and methods for treating ulcerative colitis |
| PT109154B (en) | 2016-02-12 | 2019-11-05 | Univ De Coimbra | NON-INVASIVE EYE INSERT TECHNOLOGY FOR CONTROLLED DRUG RELEASE |
| KR20220140711A (en) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3220960A (en) * | 1960-12-21 | 1965-11-30 | Wichterle Otto | Cross-linked hydrophilic polymers and articles made therefrom |
| AT251910B (en) * | 1964-07-02 | 1967-01-25 | Ceskoslovenska Akademie Ved | Process for the manufacture of soft, pliable contact lenses |
| DE1617393C2 (en) * | 1966-01-06 | 1982-11-11 | Československá akademie věd, Praha | Process for the preparation of hydrophilic crosslinked copolymers containing biologically active substances |
| US3557261A (en) * | 1967-10-05 | 1971-01-19 | Ceskoslovenska Akademie Ved | Method of centrifugally casting layered contact lenses |
| US3822089A (en) * | 1968-09-25 | 1974-07-02 | Akademie Ved | Contact lens blank or replica made from anhydrous, sparingly cross-linked hydrophilic copolymers |
| US3618604A (en) * | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| CS159361B1 (en) * | 1970-09-08 | 1975-01-31 | ||
| US3857932A (en) * | 1970-09-09 | 1974-12-31 | F Gould | Dry hydrophilic acrylate or methacrylate polymer prolonged release drug implants |
| US3641237A (en) * | 1970-09-30 | 1972-02-08 | Nat Patent Dev Corp | Zero order release constant elution rate drug dosage |
| GB1391438A (en) * | 1971-04-20 | 1975-04-23 | Contact Lens Mfg Ltd | Hydrophilic copolymers and articles formed therefrom |
| US3826258A (en) * | 1972-02-07 | 1974-07-30 | S Abraham | Gradual release medicine carrier |
| US3786812A (en) * | 1972-03-10 | 1974-01-22 | C Neefe | Contact lens for olar drug delivery |
| US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
| DE2364675C2 (en) * | 1972-12-29 | 1983-06-23 | Kuraray Co., Ltd., Kurashiki, Okayama | Copolymer consisting of a polymer main chain and polymer side chains and its use for the manufacture of articles for biomedical purposes |
| US4003991A (en) * | 1974-08-27 | 1977-01-18 | National Patent Development Corporation | Ophthalmic formulation |
| US4143949A (en) * | 1976-10-28 | 1979-03-13 | Bausch & Lomb Incorporated | Process for putting a hydrophilic coating on a hydrophobic contact lens |
| JPS5374049A (en) * | 1976-11-04 | 1978-07-01 | Toray Industries | Soft contact lens material |
| US4153641A (en) * | 1977-07-25 | 1979-05-08 | Bausch & Lomb Incorporated | Polysiloxane composition and contact lens |
| US4182802A (en) * | 1977-12-27 | 1980-01-08 | Samuel Loshaek | Hydrophilic polymers and contact lenses of high water content |
| US4158089A (en) * | 1977-12-27 | 1979-06-12 | Wesley-Jessen Inc. | Contact lenses of high water content |
| US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| US4157418A (en) * | 1978-02-08 | 1979-06-05 | Minnesota Mining And Manufacturing Company | Acrylic functional aminocarboxylic acids and derivatives as components of pressure sensitive adhesives |
| US4152508A (en) * | 1978-02-15 | 1979-05-01 | Polymer Technology Corporation | Silicone-containing hard contact lens material |
| CS216992B1 (en) * | 1980-07-21 | 1982-12-31 | Miroslav Stol | Composite polymere material for the biological and medicinal utilitation and method of preparation thereof |
| GB2087408B (en) * | 1980-11-04 | 1984-05-23 | Patel Pravin Gordhanbhai Da Co | Cross-linked hydrophilic polymers |
| US4462665A (en) * | 1981-01-29 | 1984-07-31 | The Kendall Company | Composite hydrogel-forming lens and method of making same |
| US4436887A (en) * | 1981-11-12 | 1984-03-13 | Bausch & Lomb Incorporated | N-Vinyl lactam based biomedical devices |
| US4440919A (en) * | 1981-11-12 | 1984-04-03 | Bausch & Lomb Incorporated | Low N-vinyl lactam content based biomedical devices |
| JPS58134019A (en) * | 1982-02-05 | 1983-08-10 | Ono Pharmaceut Co Ltd | Slow-releasing triple-layered film pharmaceutical containing prostaglandin and its preparation |
| US4495361A (en) * | 1983-04-29 | 1985-01-22 | Bausch & Lomb Incorporated | Polysiloxane composition with improved surface wetting characteristics and biomedical devices made thereof |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| CS239282B1 (en) * | 1983-08-17 | 1986-01-16 | Otto Wichterle | Preparation method of objects made from hydrophilic gelsnamely contact lences by polymer casting |
| US4536554A (en) * | 1984-02-22 | 1985-08-20 | Barnes-Hind, Inc. | Hydrophilic polymers and contact lenses made therefrom |
-
1985
- 1985-08-16 US US06/766,734 patent/US4713244A/en not_active Expired - Fee Related
-
1986
- 1986-07-31 CA CA000515031A patent/CA1277235C/en not_active Expired - Lifetime
- 1986-08-14 JP JP61189708A patent/JPS6296417A/en active Pending
- 1986-08-15 DE DE8686306347T patent/DE3687868T2/en not_active Expired - Fee Related
- 1986-08-15 EP EP86306347A patent/EP0212959B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3687868T2 (en) | 1993-08-19 |
| JPS6296417A (en) | 1987-05-02 |
| EP0212959B1 (en) | 1993-03-03 |
| EP0212959A2 (en) | 1987-03-04 |
| DE3687868D1 (en) | 1993-04-08 |
| US4713244A (en) | 1987-12-15 |
| EP0212959A3 (en) | 1988-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1277235C (en) | Sustained-release formulation containing an amino acid polymer with alower alkyl (c -c ), polar solvent | |
| US4668506A (en) | Sustained-release formulation containing and amino acid polymer | |
| US4931279A (en) | Sustained release formulation containing an ion-exchange resin | |
| US5137728A (en) | Ophthalmic article | |
| US20180346629A1 (en) | Biocompatible polymers and co-polymers, and uses thereof | |
| US20060018949A1 (en) | Injectable biodegradable drug delivery system | |
| CA1295941C (en) | Sustained-release formulation comprising a hydrophobic polymer system | |
| US20060100408A1 (en) | Method for forming contact lenses comprising therapeutic agents | |
| CA2726161C (en) | A peptide derivative and a composition for promoting lacrimal secretion comprising the same | |
| JPH11335301A (en) | Formulation for oculist | |
| Ueno et al. | Ocular pharmacology of drug release devices | |
| CZ386797A3 (en) | Preparation for preventing and healing inflammatory diseases | |
| US20100178315A1 (en) | Polymeric systems for controlled drug therapy | |
| US20040247681A1 (en) | Drug release system for controlled therapy | |
| JPH10324634A (en) | Ophthalmic medicine composition containing phospholipid-like polymer | |
| Schacht | Hydrogel drug delivery systems physical and ionogenic drug carriers | |
| WO1993019707A1 (en) | Ophthalmic article |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |